SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:liu-113976"
 

Search: onr:"swepub:oai:DiVA.org:liu-113976" > Phase III trial of ...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • du Bois, Andreas (author)

Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer.

  • Article/chapterEnglish2010

Publisher, publication year, extent ...

  • American society of clinical oncology,2010
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:liu-113976
  • https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-113976URI
  • https://doi.org/10.1200/JCO.2009.27.4696DOI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:121273128URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • PURPOSE: One attempt to improve long-term survival in patients with advanced ovarian cancer was thought to be the addition of more non-cross-resistant drugs to platinum-paclitaxel combination regimens. Gemcitabine was among the candidates for a third drug.PATIENTS AND METHODS: We performed a prospective, randomized, phase III, intergroup trial to compare carboplatin plus paclitaxel (TC; area under the curve [AUC] 5 and 175 mg/m(2), respectively) with the same combination and additional gemcitabine 800 mg/m(2) on days 1 and 8 (TCG) in previously untreated patients with advanced epithelial ovarian cancer. TC was administered intravenously (IV) on day 1 every 21 days for a planned minimum of six courses. Gemcitabine was administered by IV on days 1 and 8 of each cycle in the TCG arm.RESULTS: Between 2002 and 2004, 1,742 patients were randomly assigned; 882 and 860 patients received TC and TCG, respectively. Grades 3 to 4 hematologic toxicity and fatigue occurred more frequently in the TCG arm. Accordingly, quality-of-life analysis during chemotherapy showed a disadvantage in the TCG arm. Although objective response was slightly higher in the TCG arm, this did not translate into improved progression-free survival (PFS) or overall survival (OS). Median PFS was 17.8 months for the TCG arm and 19.3 months for the TC arm (hazard ratio [HR], 1.18; 95% CI, 1.06 to 1.32; P = .0044). Median OS was 49.5 for the TCG arm and 51.5 months for the TC arm (HR, 1.05; 95% CI, 0.91 to 1.20; P = .5106).CONCLUSION: The addition of gemcitabine to carboplatin plus paclitaxel increased treatment burden, reduced PFS time, and did not improve OS in patients with advanced epithelial ovarian cancer. Therefore, we recommend no additional clinical use of TCG in this population.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Herrstedt, Jørn (author)
  • Hardy-Bessard, Anne-Claire (author)
  • Müller, Hans-Helge (author)
  • Harter, Philipp (author)
  • Kristensen, Gunnar (author)
  • Joly, Florence (author)
  • Huober, Jens (author)
  • Åvall-Lundqvist, ElisabethKarolinska Institutet(Swepub:liu)eliav51 (author)
  • Weber, Béatrice (author)
  • Kurzeder, Christian (author)
  • Jelic, Svetislav (author)
  • Pujade-Lauraine, Eric (author)
  • Burges, Alexander (author)
  • Pfisterer, Jacobus (author)
  • Gropp, Martina (author)
  • Staehle, Anne (author)
  • Wimberger, Pauline (author)
  • Jackisch, Christian (author)
  • Sehouli, Jalid (author)
  • Karolinska Institutet (creator_code:org_t)

Related titles

  • In:Journal of Clinical Oncology: American society of clinical oncology28:27, s. 4162-41690732-183X1527-7755

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view